Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation

European Journal of Clinical Investigation

Volumn 43, Issue 10, 2013, Pages 1032-1038

  Krishnamoorthy, Suresh ^a   Khoo, Chee Wah ^a   Lim, Hoong S ^a   Lane, Deirdre A ^a   Pignatelli, Pasquale ^b   Basili, Stefania ^b   Violi, Francesco ^b   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Atrial fibrillation; Endothelial dysfunction; Von Willebrand factor

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ATRIAL FIBRILLATION; ENDOTHELIAL DYSFUNCTION; VON WILLEBRAND FACTOR;

AGED; ATRIAL FIBRILLATION; E-SELECTIN; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PROGNOSIS; STROKE; VON WILLEBRAND FACTOR;

EID: 84884704656     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12140     Document Type: Article

References (22)

1. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: virchow's triad revisited. Lancet 2009;373:155-66.
2. Freestone B, Lip GY. The endothelium and atrial fibrillation. The prothrombotic state revisited. Hamostaseologie 2008;28:207-12.
3. Blann AD, Choudhury A, Freestone B, Patel J, Lip GY. Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction. Int J Cardiol 2008;127:135-7.
4. Bowie EJW, Solberg LA, Fass DN, Johnson CM, Knutson GJ, Stewart ML et al. Transplantation of normal bone marrow into a pig with severe von Willebrand disease. J Clin Invest 1986;78:26-30.
5. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995;90:244-8.
6. Blann AD. von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. Z Rheumatol 1991;50:320-2.
7. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995;73:527-33.
8. Freestone B, Gustafsson F, Chong AY, Corell P, Kistorp C, Hildebrandt P et al. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure. Chest 2008;133:1203-8.
9. Gustafsson C, Blombäck M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in non-valvular atrial fibrillation. Stroke 1990;21:47-51.
10. Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000;31:828-33.
11. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-12.
12. Blann AS, Lip GYH. The endothelium in atherothrombotic disease: assessment of function, mechanism and clinical implications. Blood Coagul Firbinolysis 1998;9:297-306.
13. Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007;132:1253-8.
14. Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol 2007;99:1544-8.
15. Freestone B, Chong AY, Nuttall S, Lip GY. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res 2008;122:85-90.
16. Gasic S, Wagner OF, Fasching P, Ludwig C, Veitl M, Kapiotis S et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 1999;12(2 Pt 1):217-22.
17. Kautzky-Willer A, Fasching P, Jilma B, Waldhäusl W, Wagner OF. Persistent elevation and metabolic dependence of circulating Eselectin after delivery in women with gestational diabetes mellitus. J Clin Endocrinol Metab 1997;82:4117-21.
18. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003;107:3141-5.
19. Lane DA, Lip GY. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb Haemost 2009;101:802-5.
20. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006;37:2294-300.
21. Jansson J, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.
22. Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011;57:2496-504.